Safety Evaluation of 3K3A-APC in Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.
Also called NCT02222714
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 110 participants
- Sponsor
- Registry
-
NCT02222714
-
- Other papers using this trial's data
- Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02222714. Randomized; quadruple masking; primary purpose treatment. Start 2014-10 (registry gives no type); primary completion 2017-04-18 (actual). Results posted on 2018-11-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety Evaluation of 3K3A-APC in Ischemic Stroke
- Acronym
- RHAPSODY
- Condition
- Ischemic Stroke
- Intervention (Biological)
- 3K3A-APC
- Intervention (Drug)
- Placebo
- Lead sponsor
- ZZ Biotech, LLC
- Collaborator
- National Institute of Neurological Disorders and Stroke (NINDS)
- Collaborator
- Cedars-Sinai Medical Center
- Collaborator
- Massachusetts General Hospital
- Collaborator
- University of Iowa
Record details
- Record id
cardio:ct-nct02222714- Content hash
e47a129a0c7c3959e1da844fe96b50140b8a806c9f72a71fe2ff35b8edd506c8